— Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported earnings of $1.70 per share in the fourth-quarter 2019, vs. $1.20 per share expected. — Total revenue rose 63% to $1.41 billion, vs. $1.01 billion expected. — For FY20, company expects total product revenues of $5.1 to $5.3 billion. — VRTX stock ended Thursday’s regular trading session down 0.9%. Browse […]
— Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported earnings of $1.70 per share in the fourth-quarter 2019, vs. $1.20 per share expected. — Total revenue rose 63% to $1.41 billion, vs. $1.01 billion expected. — For FY20, company expects total product revenues of $5.1 to $5.3 billion. — VRTX stock ended Thursday’s regular trading session down 0.9%. Browse […]
— Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported earnings of $1.70 per share in the fourth-quarter 2019, vs. $1.20 per share expected.
— Total revenue rose 63% to $1.41 billion, vs. $1.01 billion expected.
— For FY20, company expects total product revenues of $5.1 to $5.3 billion.
— VRTX stock ended Thursday’s regular trading session down 0.9%.
